Magdałene Władysiuk

Jagiellonian University — Poland

Economics, Econometrics and Finance · Social Sciences

7h-index483citations16works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pharmaceutical Economics and Policy(9), Health Systems, Economic Evaluations, Quality of Life(6), Economic and Financial Impacts of Cancer(4), Biosimilars and Bioanalytical Methods(3), Pharmaceutical studies and practices(3)

Publications16 total

Corrigendum to “Utilisation Trend of Long‐Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications”
BioMed Research International·2023Open Access
The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future
Frontiers in Public Health·2021· 37 citedOpen Access
Variation in the prices of oncology medicines across Europe and the implications for the future
Generics and Biosimilars Initiative Journal·2021· 4 citedOpen Access
Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications
Expert Review of Pharmacoeconomics & Outcomes Research·2021· 71 citedOpen Access
Utilisation Trend of Long‐Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications
BioMed Research International·2021· 14 citedOpen Access
Pricing of oral generic cancer medicines in 25 European countries; findings and implications
Generics and Biosimilars Initiative Journal·2019· 44 citedOpen Access
Proposal for a regulation on health technology assessment in Europe – opinions of policy makers, payers and academics from the field of HTA
Expert Review of Pharmacoeconomics & Outcomes Research·2019· 38 citedOpen Access
Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets
Frontiers in Public Health·2018· 152 citedOpen Access
Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?
Expert Review of Clinical Pharmacology·2014· 122 cited
Pricing of Medicines In Poland – Two-Year Overview Of How The New Law Affected Costs Of Reimbursement
Value in Health·2014Open Access
PA3 Limited Access to Cataract Surgery in Poland
Value in Health·2012· 1 citedOpen Access
PDB13 Bariatric and Metabolic Surgery in China – Efficacy of Minimally Invasive Procedures
Value in Health·2012
PRM1 What is the Evidence on Using Selected Types of Sutures for Abdominal Surgery – Novel Approach to Create Dynamic Tool for Colleting and Reviewing Available Data
Value in Health·2012
PDB2 Epidemiology, Patient Burden and Related Costs of Obesity in India
Value in Health·2012Open Access
PDB8 Bariatric and Metabolic Surgery in India – Efficacy and Safety of Minimally Invasive Procedures
Value in Health·2012
PCV126 Multidimensional Non-Interventional Study to Assess Current Practice, Utilization of Resources and Costs Related to Anticoagulation Treatment in Poland – “Economedica”
Value in Health·2011

Frequent Co-authors

Brian Godman(9), Jurij Fürst(9), Jolanta Gulbinovič(8), Iris Hoxha(8), Guenka Petrova(8), Ott Laius(8), Gisbert Selke(8), Arianit Jakupi(8), Vanda Marković‐Peković(8), Ileana Mardare(8), Patricia Vella Bonanno(7), Amanj Kurdi(7), Angela Timoney(6), Robert Sauermann(6), Roberta Joppi(6), Stephen Campbell(6), Stuart McTaggart(6), R Plisko(6), Antony P. Martin(5), Steven Simoens(5)